ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023
Related news for (ADMA)
- ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
- ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
- ADMA Biologics Statement on Tariffs
- ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
